NCT03529825View on ClinicalTrials.gov

Rifaximin for Infection Prophylaxis in Hematopoietic Stem Cell Transplantation

EARLY_PHASE1CompletedINTERVENTIONAL
Enrollment

26

Participants

Timeline

Start Date

July 18, 2018

Primary Completion Date

October 19, 2020

Study Completion Date

September 10, 2021

Conditions
Microbial Colonization
Interventions
DRUG

Rifaximin

Rifaximin will be administered twice a day orally or by nasogastric tube, at a dose of 15 mg/kg divided BID with a maximum dose of 1,650 mg, day -7 to day +28 or discharge (maximum duration 36 days).

Trial Locations (1)

30322

Children's Healthcare of Atlanta, Atlanta

All Listed Sponsors
lead

Emory University

OTHER

NCT03529825 - Rifaximin for Infection Prophylaxis in Hematopoietic Stem Cell Transplantation | Biotech Hunter | Biotech Hunter